You are on page 1of 2

38086 Federal Register / Vol. 72, No.

133 / Thursday, July 12, 2007 / Notices

N.V.,all of Brussels, Belgium, Fortis DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND
Bank Nederland (Holding) N.V., HUMAN SERVICES HUMAN SERVICES
Utrecht, Netherlands, and RFS Holdings
B.V., Amsterdam, Netherlands, is Centers for Disease Control and Food and Drug Administration
revised to read as follows: Prevention
Antiviral Drugs Advisory Committee;
A. Federal Reserve Bank of Boston Ethics Subcommittee, Advisory Notice of Meeting
(Richard Walker, Community Affairs Committee to the Director (ACD),
Officer) P.O. Box 55882, Boston, Centers for Disease Control and AGENCY: Food and Drug Administration,
Massachusetts 02106-2204: Prevention (CDC) HHS.
1. Royal Bank of Scotland Group, plc, ACTION: Notice.
In accordance with section 10(a)(2) of
Edinburgh, Scotland, Banco Santander the Federal Advisory Committee Act This notice announces a forthcoming
Central Hispano, S.A., Madrid, Spain, (Pub. L. 92–463), CDC announces the meeting of a public advisory committee
Santander Holanda B.V., Delft, following meeting for the of the Food and Drug Administration
Netherlands, Fortis N.V., Utrecht, aforementioned subcommittee. (FDA). At least one portion of the
Netherlands, Fortis S.A./N.V.,Fortis meeting will be closed to the public.
Times and dates: 1 p.m.–5:30 p.m., August
Brussels, S.A./N.V., Fortis Bank, all of 9, 2007. 8:30 a.m.–3:30 p.m., August 10, Name of Committee: Antiviral Drugs
Brussels, Belgium, Fortis Bank 2007. Advisory Committee.
Nederland (Holding) N.V., Utrecht, Place: CDC, 1825 Century Center, General Function of the Committee:
Netherlands, and RFS Holdings B.V., Conference Room 1 A/B, Atlanta, GA 30345. To provide advice and
Amsterdam, Netherlands; to control Status: Open to the public, limited only by recommendations to the agency on
ABN AMRO Holding N.V. Amsterdam, the space available. The meeting room FDA’s regulatory issues.
accommodates approximately 75 people. To Date and Time: The meeting will be
Netherlands, and thereby indirectly accommodate public participation in the
acquire ABN AMRO North American held on September 5, 2007, from 8 a.m.
meeting, a conference telephone line will be
Holding Company, LaSalle Bank available. The public is welcome to
to 4 p.m. and on September 6, 2007,
Corporation, LaSalle Bank National participate during the public comment from 9 a.m. to 1 p.m.
Association, all of Chicago, Illinois, and periods by calling (866) 919–3560 and Location: On September 5, 2007, the
LaSalle Bank Midwest National entering code 4168828. The public comment committee will meet at the Hilton
Association, Troy, Michigan. In periods are tentatively scheduled from 4:45 Washington DC/Silver Spring, The
p.m.–5 p.m. on August 9, 2007 and from 3 Ballrooms, 8727 Colesville Rd., Silver
connection with this proposal Fortis p.m.–3:15 p.m. on August 10, 2007. Spring, MD. The hotel telephone
Bank Nederland (Holding) N.V., Purpose: The Ethics Subcommittee will number is 301–589–5200. On September
Santander Holand B.V. and RFS provide counsel to the ACD, CDC regarding 6, 2007, the committee will meet in
Holdings B.V. have applied to become a broad range of public health ethics
questions and issues arising from programs,
closed session at FDA, White Oak
bank holing companies. Headquarters, rm. 2046, 10903 New
scientists, and practitioners.
In addition, each of The Royal Bank Matters To Be Discussed: Agenda items Hampshire Ave., Silver Spring, MD.
of Scotland Group, plc, The Royal Bank will include: Ethical Guidance for Public Contact Person: Cicely Reese, Center
of Scotland plc, RBSG International Health Emergency Preparedness and for Drug Evaluation and Research (HFD–
Holdings Limited, all of Edinburgh, Response, Ethical Issues relating to CDC 21), Food and Drug Administration,
Scotland, and Citizens Financial Group, Partnerships, Public Health Ethics and 5600 Fishers Lane (for express delivery,
Genomics, Ethical Guidance for Non- 5630 Fishers Lane, rm. 1093), Rockville,
Inc., Providence, Rhode Island, has Research Data Collections, and Updates on
applied to acquire control of ABN MD 20857, 301–827–7001, FAX: 301–
Ethical Issues relating to Pandemic Influenza
AMRO North American Holding Preparedness. Agenda items are subject to
827–6776, e-mail:
Company, LaSalle Bank Corporation, change as priorities dictate. Cicely.Reese@fda.hhs.gov, or FDA
LaSalle Bank National Association, and For security reasons, members of the Advisory Committee Information Line,
LaSalle Bank Midwest National public interested in attending the meeting 1–800–741–8138 (301–443–0572 in the
Association in a transfer subsequent to should contact the person below. The Washington, DC area), code
deadline for notification of attendance is 3014512531. Please call the Information
the acquisition of control of ABN AMRO August 2, 2007. Line for up-to-date information on this
Holding N.V. Contact Person for More Information: Drue meeting. A notice in the Federal
Comments on this application must Barrett, Ph.D., Designated Federal Official, Register about last minute modifications
be received by July 25, 2007. Ethics Subcommittee, CDC, 1600 Clifton
Road, NE., M/S D–50, Atlanta, Georgia
that impact a previously announced
Board of Governors of the Federal Reserve 30333. Telephone (404) 639–4690. E-mail: advisory committee meeting cannot
System, July 9, 2007. dbarrett@cdc.gov. always be published quickly enough to
Robert deV. Frierson, The Director, Management Analysis and provide timely notice. Therefore, you
Services Office, has been delegated the should always check the agency’s Web
Deputy Secretary of the Board. authority to sign Federal Register notices site and call the appropriate advisory
[FR Doc. E7–13530 Filed 7–11–07; 8:45 am] pertaining to announcements of meetings and committee hot line/phone line to learn
BILLING CODE 6210–01–S other committee management activities, for about possible modifications before
both CDC and the Agency for Toxic coming to the meeting.
Substances and Disease Registry.
Agenda: On September 5, 2007, the
Dated: July 5, 2007. committee will discuss new drug
Elaine L. Baker, application (NDA) 22–145, raltegravir
rwilkins on PROD1PC63 with NOTICES

Acting Director, Management Analysis and potassium, integrase inhibitor 400


Services Office Centers for Disease Control milligram tablets, Merck & Co., Inc., for
and Prevention (CDC). the treatment of Human
[FR Doc. E7–13523 Filed 7–11–07; 8:45 am] Immunodeficiency Virus-1 (HIV–1)
BILLING CODE 4163–18–P infection in combination with other

VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\12JYN1.SGM 12JYN1
Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices 38087

antiretroviral agents in treatment- disabilities or special needs. If you The current invention describes a
experienced patients with evidence of require special accommodations due to family of short peptides that bind to the
HIV–1 replication despite ongoing adisability, please contact Cicely Reese N-terminus domains of STAT proteins
antiretroviral therapy. On September 6, at least 7 days in advance of the and their use as therapeutic agents.
2007, the meeting will be closed to meeting. These compounds are the first inhibitors
permit discussion and review of trade Notice of this meeting is given under that can directly bind to N-domains of
secret and/or confidential information. the Federal Advisory Committee Act (5 STATs and exhibit a direct inhibitory
FDA intends to make background U.S.C. app. 2). effect. STAT1, 3, and 5 inhibitors can
material available to the public no later serve as potent therapeutic agents for
Dated: July 5, 2007.
than 2 business days before the meeting. the treatment of a variety of tumors and
If FDA is unable to post the background Randall W. Lutter,
STAT 4 inhibitors can be used to
material on its Web site prior to the Deputy Commissioner for Policy.
control autoimmune disorders.
meeting, the background material will [FR Doc. E7–13560 Filed 7–11–07; 8:45 am] Applications and Modality: Other
be made publicly available at the BILLING CODE 4160–01–S applications for this technology include
location of the advisory committee using STAT1, STAT3 and STAT5
meeting, and the background material inhibitors for the treatment of various
will be posted on FDA’s Web site after DEPARTMENT OF HEALTH AND tumors; using STAT4 inhibitors to
the meeting. Background material is HUMAN SERVICES control autoimmune disorders; and
available at http://www.fda.gov/ohrms/ using STAT inhibitors as research tools
dockets/ac/acmenu.htm, click on the National Institutes of Health
to study the function of STAT proteins.
year 2007 and scroll down to the Market: There were approximately
Government-Owned Inventions;
appropriate advisory committee link. 600,000 deaths from cancer related
Procedure: On September 5, 2007, Availability for Licensing
diseases estimated in 2006. In 2006, the
from 8 a.m. to 4 p.m., the meeting is AGENCY: National Institutes of Health, cancer drug market was estimated to be
open to the public. Interested persons Public Health Service, HHS. $25 billion.
may present data, information, or views, Development Status: The technology
ACTION: Notice.
orally or in writing, on issues pending is currently in the pre-clinical stage of
before the committee. Written SUMMARY: The inventions listed below development.
submissions may be made to the contact are owned by an agency of the U.S. Inventors: Nadya I. Tarasova et al.
person on or before August 21, 2007. Government and are available for (NCI).
Oral presentations from the public will licensing in the U.S. in accordance with Relevant Publications: A manuscript
be scheduled between approximately 1 35 U.S.C. 207 to achieve expeditious directly related to the above technology
p.m. and 2 p.m. Those desiring to make commercialization of results of will be available as soon as it is
formal oral presentations should notify federally-funded research and accepted for publication.
the contact person and submit a brief development. Foreign patent Patent Status: U.S. Provisional
statement of the general nature of the applications are filed on selected Application No. 60/940,916 filed 30
evidence or arguments they wish to May 2007 (HHS Reference No. E–164–
inventions to extend market coverage
present, the names and addresses of 2007/0–US–01).
for companies and may also be available
proposed participants, and an Licensing Status: Available for
for licensing.
indication of the approximate time exclusive and non-exclusive license.
requested to make their presentation on ADDRESSES: Licensing information and Licensing Contact: Adaku
or before August 14, 2007. Time allotted copies of the U.S. patent applications Nwachukwu, J.D.; 301/435–5560;
for each presentation may be limited. If listed below may be obtained by writing madua@mail.nih.gov.
the number of registrants requesting to to the indicated licensing contact at the
Office of Technology Transfer, National Benztropinamine Analogs as Dopamine
speak is greater than can be reasonably
Institutes of Health, 6011 Executive Transport Inhibitors
accommodated during the scheduled
open public hearing session, FDA may Boulevard, Suite 325, Rockville, Description of Technology: Dopamine
conduct a lottery to determine the Maryland 20852–3804; telephone: 301/ is a neurotransmitter that is directly
speakers for the scheduled open public 496–7057; fax: 301/402–0220. A signed involved in motor activity, motivation
hearing session. The contact person will Confidential Disclosure Agreement will and reward, and cognition. The
notify interested persons regarding their be required to receive copies of the dopamine transporter is expressed on
request to speak by August 13, 2007. patent applications. the plasma membrane of dopamine
Closed Committee Deliberations: On neurons and is responsible for clearing
Compounds Binding to the N-Terminal
September 6, 2007, from 9 a.m. to 1 dopamine released into the extracellular
Domains of STAT Proteins as
p.m., the meeting will be closed to space, thereby regulating
Therapeutic Agents
permit discussion and review of trade neurotransmission. The dopamine
secret and/or confidential information Description of Technology: Signal transporter plays a significant role in
(5 U.S.C. 552b(c)(4)). The committee transducer and activator transcription neuropsychiatric diseases, such as
will be asked to provide feedback on a (STAT) proteins, specifically STAT1, 2, Parkinson’s disease, drug abuse
Phase 3 protocol in the development of 3, 4, 5a, 5b, and 6, are involved in the (especially cocaine addiction), Attention
a new indication. cellular and biological processes of cell Deficit Disorder/Attention Deficit
Persons attending FDA’s advisory proliferation, differentiation, apoptosis, Hyperactivity Disorder (ADD/ADHD),
committee meetings are advised that the host defense, and transformation. narcolepsy and a number of other CNS
agency is not responsible for providing Constitutively active STAT proteins disorders. Therefore, the dopamine
rwilkins on PROD1PC63 with NOTICES

access to electrical outlets. occur in many human tumor cells and transporter is a target for research and
FDA welcomes the attendance of the cells transformed by oncoproteins. potential therapeutics for the treatment
public at its advisory committee Inhibiting these STAT proteins has great of these indications.
meetings and will make every effort to therapeutic potential in the treatment of Benztropine and its analogs are an
accommodate persons with physical certain cancers. important class of dopamine transport

VerDate Aug<31>2005 16:42 Jul 11, 2007 Jkt 211001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\12JYN1.SGM 12JYN1